Contents

Current Drug Targets - CNS & Neurological Disorders, Volume 2 - Number 3

Recent Knowledge on Molecular Components of Lewy Bodies Discloses Future Therapeutic Strategies in Parkinsons Disease

, 2(3): 149 - 152

F. Fornai, P. Lenzi, M. Gesi, M. Ferrucci, G. Lazzeri, G. Natale, S. Ruggieri and A. Paparelli


DOI: 10.2174/1568007033482904




FK506 and Its Analogs - Therapeutic Potential for Neurological Disorders

, 2(3): 153 - 162

Alexa Klettner and Thomas Herdegen


DOI: 10.2174/1568007033482878




Role of Acetylcholinesterase Inhibitors in the Metabolism of Amyloid Precursor Protein

, 2(3): 163 - 171

M. Pakaski and P. Kasa


DOI: 10.2174/1568007033482869




Calpain and Its Involvement in the Pathophysiology of CNS Injuries and Diseases: Therapeutic Potential of Calpain Inhibitors for Prevention of Neurodegeneration

, 2(3): 173 - 189

Swapan K. Ray and Naren L. Banik


DOI: 10.2174/1568007033482887




The Vasopressin V1b Receptor as a Therapeutic Target in Stress-related Disorders

, 2(3): 191 - 200

Guy Griebel, Jacques Simiand, Jeanne Stemmelin, Claudine Serradeil-Le Gal and Regis Steinberg


DOI: 10.2174/1568007033482850




CART Peptides as Targets for CNS Drug Development

, 2(3): 201 - 205

Richard G. Hunter and Michael J. Kuhar


DOI: 10.2174/1568007033482896




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science